ArticleMedicine2025
Multiple skin tumors in a patient treated with orelabrutinib for mantle-cell lymphoma: Case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
rationaleMantle-cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma. Bruton tyrosine kinase inhibitors (BTKi) significantly improve the prognosis of MCL, but their long-term use may induce immunosuppression-related complications, including secondary malignancies. First-generation BTKi such as Ibrutinib have been reported to be associated with the development of skin cancer. PATIENT CONCERNS: A 77-year-old male patient with MCL treated with the next-generation highly selective BTKi Orelabrutinib (150mg/ day) developed multiple different types of skin tumors. DIAGNOSES: Skin pathological examination confirmed basal cell carcinoma of the nose, squamous cell carcinoma, actinic keratosis and seborrheic keratosis of the chest skin.
interventionsOrelabrutinib was suspended and switched to chemotherapy. The nasal and chest skin tumors were resected, the nasal wound was repaired with adjacent flap, and the chest wound was repaired with skin grafting. OUTCOMES: The wound recovered well after the operation, but the patient died of multiple organ failure due to pulmonary infection 5 months later. LESSONS: Orelabrutinib may be associated with multiple skin tumors, and the mechanism may be through complex immune dysregulation. It is recommended that patients receiving long-term BTKi therapy undergo regular dermatological examinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.